UBS O'Connor’s VistaGen Therapeutics VTGN Stock Holding History

UBS O'Connor’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,717	Closed	-$336K	–	1013
2022 Q2	$336K	Buy	+12,717	New	+$449K	﹤0.01%	832

Other funds holding VTGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS O'Connor's VTGN Position: Q3 2022 in Review

UBS O'Connor sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 12,717 shares — an estimated $336K sold.

UBS O'Connor first reported a position in VTGN in Q2 2022 and held it in 1 quarter. The position peaked at $336K in Q2 2022. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

UBS O'Connor reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
UBS O'Connor sold 12,717 VistaGen Therapeutics shares in Q3 2022, an estimated $336K.
UBS O'Connor first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 1 quarter.
UBS O'Connor's VistaGen Therapeutics position peaked at $336K in Q2 2022.
92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.